Filtros de búsqueda

Lista de obras de

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

artículo científico publicado en 2019

Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model.

artículo científico publicado en 2018

Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.

artículo científico publicado en 2011

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

artículo científico publicado en 2008

Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.

artículo científico publicado en 2017

In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.

artículo científico publicado en 2017

Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations

artículo científico publicado en 2015

MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib

artículo científico publicado en 2020

Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance

artículo científico publicado en 2019

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer

scientific article published on 06 January 2020

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

artículo científico publicado en 2012

Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion

artículo científico publicado en 2020

T790M is associated with a favorable prognosis in Japanese patients treated with an EGFR-TKI ⬇️

artículo científico publicado el 14 de febrero de 2012

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

artículo científico publicado en 2020

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda